CN113710272A - 用于治疗类风湿性关节炎的生物标记物 - Google Patents

用于治疗类风湿性关节炎的生物标记物 Download PDF

Info

Publication number
CN113710272A
CN113710272A CN202080027376.5A CN202080027376A CN113710272A CN 113710272 A CN113710272 A CN 113710272A CN 202080027376 A CN202080027376 A CN 202080027376A CN 113710272 A CN113710272 A CN 113710272A
Authority
CN
China
Prior art keywords
rheumatoid arthritis
weeks
amino acid
fkn
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080027376.5A
Other languages
English (en)
Chinese (zh)
Inventor
安田信之
山田知广
田胡文利
北条诚一郎
今井俊夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN113710272A publication Critical patent/CN113710272A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
CN202080027376.5A 2019-04-23 2020-04-20 用于治疗类风湿性关节炎的生物标记物 Pending CN113710272A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019081452 2019-04-23
JP2019-081452 2019-04-23
PCT/JP2020/017016 WO2020218232A1 (ja) 2019-04-23 2020-04-20 関節リウマチ治療のためのバイオマーカー

Publications (1)

Publication Number Publication Date
CN113710272A true CN113710272A (zh) 2021-11-26

Family

ID=72942731

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080027376.5A Pending CN113710272A (zh) 2019-04-23 2020-04-20 用于治疗类风湿性关节炎的生物标记物

Country Status (5)

Country Link
US (1) US20220205980A1 (https=)
EP (1) EP3960198A4 (https=)
JP (1) JP7550142B2 (https=)
CN (1) CN113710272A (https=)
WO (1) WO2020218232A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4238578A4 (en) * 2020-10-30 2024-09-11 Eisai R&D Management Co., Ltd. PHARMACEUTICAL COMPOSITION

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180111988A1 (en) * 2016-10-26 2018-04-26 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating rheumatoid arthritis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4263391B2 (ja) 2001-03-19 2009-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用
US20020192212A1 (en) * 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
EP1806145B1 (en) 2004-10-29 2017-08-16 Eisai R&D Management Co., Ltd. Remedy for inflammatory diseases
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
BR112012002333A2 (pt) * 2009-08-06 2017-07-18 Neuraltus Pharmaceuticals Inc método de reduzir os efeitos colaterais e método de potencializar o efeito de um imunomodulador administrado a um sujeito que dele necessita; métodos para tratar doença associada com excesso de ativação de monócitos para macrófagos ativados, diabetes tipo ii ou complicações relacionadas, doença associada com a migração de monócitos ou macrófagos ativados, doença associada a excesso de produção de scd14 e/ou scd163 por macrófagos ativados; composto de cloreto de sódio; composição farmacêutica; método para diagnosticar uma doença relacionada com macrófagos em um sujeito; e método para determinar a eficácia do tratamento com um agente oxidante para uma doença relacionada a macrófagos em um sujeito.
JO3437B1 (ar) * 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
US8961967B2 (en) * 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
JP2017193541A (ja) 2016-04-19 2017-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチを治療するための医薬組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180111988A1 (en) * 2016-10-26 2018-04-26 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating rheumatoid arthritis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LUIS CHARA等: "Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis", ARTHRITIS RESEARCH & THERAPY, vol. 14, no. 4, XP021133943, DOI: 10.1186/ar3928 *
TOSHIO IMAI等: "Therapeutic intervention of inflammatory/ immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway", INFLAMMATION AND REGENERATION, vol. 36, no. 1, pages 2, XP055550117, DOI: 10.1186/s41232-016-0017-2 *

Also Published As

Publication number Publication date
US20220205980A1 (en) 2022-06-30
JPWO2020218232A1 (https=) 2020-10-29
EP3960198A1 (en) 2022-03-02
EP3960198A4 (en) 2023-01-11
JP7550142B2 (ja) 2024-09-12
WO2020218232A1 (ja) 2020-10-29

Similar Documents

Publication Publication Date Title
JP6250109B2 (ja) Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法
CN108064168B (zh) 抗cd40l抗体和用于治疗cd40l相关疾病或病症的方法
SG187945A1 (en) Anti-ox40 antibodies and methods of using the same
JP2020109108A (ja) 関節リウマチの治療における、又は、鎮痛剤としての使用のための抗体中和ｇｍ−ｃｓｆ
CN116249710A (zh) 治疗性抗体
CN118591389A (zh) 使用萨特利珠单抗治疗中枢神经系统（cns）的脱髓鞘疾病
JP2024069230A (ja) 慢性回腸嚢炎の治療のための方法
KR20180120706A (ko) 이식편대숙주 질환을 예방하는 방법
AU2017234010B2 (en) Methods of treating or preventing graft versus host disease
EP2425250B1 (en) Methods for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
Steenholdt Personalized therapy with TNF-inhibitors in Crohn's disease: optimizing treatment outcomes by monitoring drug levels and anti-drug antibodies
JP7550142B2 (ja) 関節リウマチ治療のためのバイオマーカー
US20110053209A1 (en) Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
Bouden et al. No correlation between anti-drug antibodies and therapeutic response in Tunisian patients with chronic inflammatory diseases treated by TNF blockers
CN116472059A (zh) Il-18拮抗剂用于治疗和/或预防特应性皮炎或相关病症的用途
US20110104153A1 (en) Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
AU2014259523B2 (en) Methods of treating psoriatic arthritis using IL-17 antagonists
EP3159007A1 (en) Pharmaceutical composition for treating rheumatoid arthritis
CN118715244A (zh) 治疗性抗体
KR20250087734A (ko) T-림프구 매개 질환의 치료 방법
KR20240139085A (ko) 치료 항체
HK40083901A (en) Methods of treating rheumatoid arthritis using il-17 antagonists
HK40035240B (en) Methods of treating psoriatic arthritis using il-17 antagonists
HK1229257B (en) Methods of treating ankylosing spondylitis using anti-il-17 antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination